About: Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.17 (-5.53%)
EPRX NASDAQ Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc. Common Stock share price
Atividade de preço de EPRX
Último preço
$ 7,170
Variação (24h)
-0,42 USD (5,53%)
Volume
37.49K
Volume (média 4 sem.)
-
Abertura
$ 7,61
Variação do dia
$ 7,09 - $ 7,61
Fechamento anterior
$ 7,59
Último negócio
23 Oct, 2:48 pm GMT+0
Atrasado
23 Oct, 2:48 pm GMT+0
EPRX price performance
Atrasado
23 Oct, 2:48 pm GMT+0
quote.marketSignals